Capital Fund Management (CFM)
GPCR icon

Capital Fund Management (CFM)’s Structure Therapeutics GPCR Stock Holding History

Capital Fund Management (CFM)’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
37,281
+4,845
+15% +$214K 0.01% 1429
2026
Q1 		$1.56M Buy
+32,436
New +$2.22M 0.01% 1486
2025
Q3 		– Sell
-14,350
Closed -$298K – 2546
2025
Q2 		$298K Sell
14,350
-65,306
-82% -$1.44M ﹤0.01% 2274
2025
Q1 		$1.38M Buy
79,656
+12,521
+19% +$307K ﹤0.01% 1553
2024
Q4 		$1.82M Buy
67,135
+17,007
+34% +$603K ﹤0.01% 1526
2024
Q3 		$2.2M Buy
+50,128
New +$1.94M 0.01% 1389

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Capital Fund Management (CFM)'s GPCR Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its Structure Therapeutics (GPCR) stake by 15% in Q2 2026, buying an estimated $214K and bringing the position to 37,281 shares worth $2M. The position accounts for 0.01% of the portfolio, ranked #1429.

Capital Fund Management (CFM) first reported a position in GPCR in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.2M in Q3 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Capital Fund Management (CFM) held 37,281 shares of Structure Therapeutics worth $2M as of Q2 2026.
  • Capital Fund Management (CFM) bought 4,845 Structure Therapeutics shares in Q2 2026, an estimated $214K.
  • Structure Therapeutics made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1429 holding.
  • Capital Fund Management (CFM) first reported a position in Structure Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Capital Fund Management (CFM)'s Structure Therapeutics position peaked at $2.2M in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.